Entrada Therapeutics, Inc. (TRDA)
6.565
-0.54
(-7.67%)
USD |
NASDAQ |
Sep 10, 14:41
Entrada Therapeutics EPS Diluted (Quarterly) : -1.013 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.013 |
| March 31, 2026 | -0.9493 |
| December 31, 2025 | -0.9414 |
| September 30, 2025 | -1.064 |
| June 30, 2025 | -1.043 |
| March 31, 2025 | -0.4224 |
| December 31, 2024 | 0.0263 |
| September 30, 2024 | -0.3454 |
| June 30, 2024 | 1.550 |
| March 31, 2024 | 0.6754 |
| December 31, 2023 | -0.286 |
| September 30, 2023 | 1.020 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.7818 |
| March 31, 2023 | -0.2062 |
| December 31, 2022 | -0.7856 |
| September 30, 2022 | -0.8032 |
| June 30, 2022 | -0.7411 |
| March 31, 2022 | -0.6935 |
| December 31, 2021 | -0.5908 |
| September 30, 2021 | -0.4623 |
| June 30, 2021 | -0.3168 |
| March 31, 2021 | -0.2685 |
| December 31, 2020 | -0.2776 |
| September 30, 2020 | -0.224 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.76M |
| Revenue (Quarterly) | 0.898M |
| Total Expenses (Quarterly) | 43.66M |
| Enterprise Value | 102.38M |
| Gross Profit Margin (Quarterly) | 10.91% |
| Profit Margin (Quarterly) | -4.76K% |
| Earnings Yield | -60.44% |
| Normalized Earnings Yield | -60.44 |